About us

We Care for the Rare

Egetis Therapeutics is an innovative purpose-driven, global rare disease company dedicated to developing and delivering treatments for rare diseases with significant unmet medical need.

By combining scientific expertise, clinical development capabilities and a patient-centered approach, we work to bring meaningful therapies to people living with rare diseases where few or no treatment options exist. Our activities span late-stage development, regulatory approval, market access and commercialization, helping ensure that innovative treatments can reach the patients who need them most.

a mother holding a child

Why We Exist

Rare diseases affect an estimated 300 million people worldwide1, yet most rare diseases still lack approved treatment options. For many patients and families, this means years of uncertainty, limited treatment options and significant daily challenges.

This reality is why we care for the rare.

By focusing on diseases with significant unmet medical need. We exist to solve serious unmet medical needs for patients who have few or no treatment alternatives.

How We Create Impact

Patient need directs our choices. We concentrate our expertise and resources where needs are urgent, options are limited, and focused action can make a meaningful difference. By staying close to the science, patients and the realities of delivering new therapies, we turn insight into purposeful decisions and action.

 

Our Values

Courage

We challenge convention and pursue opportunities that have the potential to improve the lives of people living with rare diseases.

Commitment

We are dedicated to delivering high-quality results with integrity, accountability and a long-term focus on patient impact.

Collaboration

We believe the best outcomes are achieved when patients, healthcare professionals, partners and employees work together towards a common goal.

Our motivation

Around 300 million people worldwide live with a rare disease, while most rare diseases still lack approved treatment options. This reality drives our commitment to develop and commercialize therapies that can make a meaningful difference for patients and families.

1 The Lancet Global Health. (2024). Global perspectives on rare diseases: Bridging health and equity gaps. The Lancet Global Health. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00056-1/fulltext

Skip to toolbar